Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium thiosulfate pentahydrate, quantity: 2.5 g - injection, solution - excipient ingredients: sulfuric acid; sodium metabisulfite; dibasic sodium phosphate dodecahydrate; water for injections; sodium hydroxide - dbl sodium thiosulfate injection is indicated as an antidote in the treatment of cyanide poisoning. it is frequently used in conjunction with sodium nitrite. sodium thiosulfate is also indicated to prevent sodium nitroprusside induced cyanide poisoning.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sodium thiosulfate pentahydrate 250 mg/ml - solution for injection - 25% w/v - active: sodium thiosulfate pentahydrate 250 mg/ml excipient: dibasic sodium phosphate dodecahydrate sodium metabisulfite water for injection - dbl™ sodium thiosulfate injection is indicated as an antidote in the treatment of cyanide poisoning. it is frequently used in conjunction with sodium nitrite. sodium thiosulfate is also indicated to prevent sodium nitroprusside induced cyanide poisoning

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - sodium sulfate decahydrate 100% - powder for oral solution - 100 % - active: sodium sulfate decahydrate 100%

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium selenate decahydrate, quantity: 467 microgram (equivalent: selenium, qty 100 microgram) - injection, intravenous infusion - excipient ingredients: water for injections - indications as at 01 march 1998 : this formulation is indicated for use as a supplement to iv solutions given for tpn. administation of the solution in tpn solutions helps to maintain plasma levels of copper, manganese, and selenium and to prevent depletion of endogenous stores of these trace elements and subsequent deficiency symptoms. cancer: prophylaxis of malignant neoplasms via selenium supplementation.

Israel - engelsk - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - engelsk - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

australasian medical & scientific ltd - sodium tetradecyl sulfate, quantity: 30 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; sodium hydroxide - indications as at 09 june 2005 : the solution is designed for injection directly into the lumen of the varicose vein and is used as a sclerosant in the treatment of uncomplicated varicose veins of the leg by compression sclerotherapy. the strength of fibrovein selected depends on the size of the veins to be treated. fibrovein 3% is for the treatment of large superficial varicose veins. fibrovein 1% is for the treatment of small varicose veins and the larger venules. minor venules and spider veins (venous flares) should be treated with fibrovein 0.5% or 0.2%. the selection of the incorrect strength particularly in the case of minor venules and spider veins is liable to give rise to adverse reactions.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

ksj pharmatech - neostigmine methylsulfate, quantity: 2.5 mg; glycopyrronium bromide, quantity: 0.5 mg - injection, solution - excipient ingredients: water for injections; citric acid; sodium hydroxide; dibasic sodium phosphate dodecahydrate - reversal of residual non-depolarising (competitive) neuromuscular block.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

fit-bioceuticals pty ltd - sodium sulfate decahydrate, quantity: 195 mg (equivalent: sodium, qty 63.1 mg); silicon dioxide, quantity: 33 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; maize starch; soy polysaccharide; lactose monohydrate; acacia; magnesium stearate - mineral supplement.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.